Drug intelligence / Profile preview

RJ031

Development stage: Preclinical
Lead developer: Risen
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics

Overview

RJ031 is a dual-target small interfering RNA (siRNA) therapeutic candidate being developed by Risen Pharma for the treatment of Alzheimer's disease. The drug utilizes RNA interference to silence the expression of two undisclosed genetic targets involved in the progression of the disease. Currently in the IND-enabling stage, RJ031 represents a novel approach to neurodegenerative disease by potentially addressing multiple pathological pathways simultaneously.

Beyond the preview

Go deeper on RJ031.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RJ031.

Explore the full profile